Stratified Medicine Programme

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: Cancer Research UK
  • Initiator Type: Government
  • Disease focus:
    Oncology
  • Location: Europe

Abstract

Cancer Research UK’s Stratified Medicine Programme is a vital step toward making personalized treatments a reality in the U.K. Together with AstraZeneca, Pfizer, and the U.K. government’s Technology Strategy Board, the program is building the model for a national service that will routinely test tumors for certain genetic changes. As new targeted treatments become available, this system will give doctors access to tests that will help them decide which treatments are best for each patient. At the same time, information about patients’ test results and their treatments will help researchers investigate how certain genetic changes can affect the outcome of particular treatments — information that will help to save more lives in the future.

Financing

The entire program is funded at £5.5 million by Cancer Research UK, AstraZeneca, Pfizer, and the U.K. Technology Strategy Board.

Data Sharing

The data will be stored at the Eastern Cancer Registry and Information Centre. Cancer registries have been granted authority to store this type of data by law. The information is kept strictly
confidential and is only accessible to authorized people. The partners will have access to some sample material for ethically approved research (e.g., testing for newly discovered genetic
faults).

Cancer Research UK wants the best use to be made of the samples that have been given for research, so the charity is setting up an access committee for researchers who want to use the
data.

Impact/Accomplishment

In the two years up to July 2013, more than 9,000 people with melanoma, breast, bowel, lung, prostate, and ovarian cancer had their tumors tested.

More than 8,000 patient records are now securely stored in a research database, with access for researchers planned for 2014.

The program has switched from individual gene tests to Next Generation Sequencing, which tests multiple genes at the same time, saving time and money.

Importantly, it now has a dedicated, nationwide network of hospitals and individuals experienced in providing genetic testing and has laid the foundations from SMP2.

Sponsors & Partners

AstraZeneca

Bristol-Myers Squibb

Cancer Research UK

Oracle

Pfizer

Public Health England

Roche

The Catalyst Club

University of Oxford


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.